2336. Infectious Complications as a Predictor of Mortality and Failure to Achieve Complete-response in Patients with Non-Hodgkin Lymphoma
Session: Poster Abstract Session: Infections in the Compromised Host
Saturday, October 29, 2016
Room: Poster Hall
  • poster IDWeek_2.pdf (281.3 kB)
  • Background:ÂÂChemotherapeutic regimens containing the monoclonal antibody rituximab have demonstrated improvement in the overall and disease-free survival in patients with non-Hodgkin lymphoma (NHL). Infectious diseases complications are important adverse events related to rituximab increasing the morbidity and mortality of those patients.

    Methods:ÂÂRetrospective, single-center, observational and analytical study that included all patients diagnosed with NHL from January 1, 2011 to December 31, 2012 at Instituto Nacional de Cancerología (INCan) in Mexico City. Demographics, comorbidities, outcomes and infections grade 3 to 5 (Common Terminology Criteria for Adverse Events version 4.0, NCI, NIH) were registered on a standardized form. Survival analysis and multivariate analysis were conducted.

    Results:ÂÂTwo-hundred sixty five patients were included, 108 (40.8%) were men; mean age was 60+ 15 years; 46 (17%) had diabetes mellitus. Two hundred and eleven (80%) had an aggressive type of lymphoma: diffuse large B-cell, Burkitt or mantle-cell; 180 (67.9%) were on stage 3 or 4 (Ann Arbor staging system) and 261 (99%) received the standard first line treatment: rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Eighty-five (32%) developed an infection. There weren´t significant differences in baseline characteristics between patients that developed an infection vs. patients with no complication (n=85, 32% vs. n=180, 68% respectively). The multivariate analysis showed that age >60 years (OR 3.7, CI95% 1.7-8.2, p=0.001); failure to achieve complete-response (OR 3.9, CI95% 1.8-8.8, p=0.001) and development of an infectious complication (OR 7.9, CI95% 3.8-17, p<0.001) increase the risk of death. Overall survival in patients with and without infections is shown in

    Conclusion:The development of infectious complications in patients with NHL receiving first line chemotherapy with R-CHOP increases the risk of mortality and failure to achieve complete-response.

    Patricia Meza-Meneses, MD1, Diana Vilar-Compte, MD, MSc2, Patricia Cornejo-Juarez, MD, MSc2 and Patricia Volkow, MD3, (1)Infectious Diseases, Hospital Regional de Alta Especialidad Ixtapaluca, Estado de México, Mexico, (2)Infectious Diseases, Instituto Nacional de Cancerología, Mexico City, Mexico, (3)Infectious Diseases Department, Instituto Nacional de Cancerologia, Mexico City, Mexico


    P. Meza-Meneses, None

    D. Vilar-Compte, None

    P. Cornejo-Juarez, None

    P. Volkow, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.